Advanced Cancer Therapeutics
Learn more about our founders and the management team at Advanced Cancer Therapeutics.
about advanced cancer therapeutics
Advanced Cancer Therapeutics (ACT) is leading innovation within the biotechnology industry. Founded in January 2007, the company is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center and the University of Louisville Research Foundation, ACT will establish exclusive rights to specific novel therapeutics and fast-track these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.
ACT's compound PFK-158 featured in CEO/CFO Magazine; Announces MD Anderson and UT Health Science Center San Antonio added as clinical trial sites. Click HERE to read more.
ACT was awarded #3 in The University of Houston's Cougar 100 companies! Click HERE to read more.
ACT's compound PFK-158 has been chosen by Informa and Kantar Health as one of the "2014 Top 10 Most Interesting Oncology Projects to Watch". Click HERE to read more.
ACT is currently conducting a Phase I, open label, dose escalation, multicenter clinical trial in patients with advanced solid tumors. The study is to evaluate the safety, tolerability and antitumor activity of PFK158, a small molecule therapeutic candidate. The centers involved with the study are the MD Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, the Lombardi Cancer Center at Georgetown
University and the Brown Cancer at the University of Louisville.